When was BrainStorm Cell founded?

BrainStorm Cell was founded in 2000 and raised its 1st funding round 12 years after it was founded.

Where is BrainStorm Cell located?

BrainStorm Cell is headquartered in Petah Tikva, Israel.

How many employees does BrainStorm Cell have?

As of Mar 31, 2026, the latest employee count at BrainStorm Cell is 30.

Is BrainStorm Cell a funded company?

BrainStorm Cell is a funded company, having raised an undisclosed amount across 10 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Jul 27, 2012.

When was the latest funding round of BrainStorm Cell?

BrainStorm Cell's latest funding was a $***** Post IPO round on Feb 09, 2026, with participation from 0 investor.

Where does BrainStorm Cell rank among its competitors?

BrainStorm Cell ranks 59th amongst 492 active competitors, of which 165 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was BrainStorm Cell, which secured $1M in Feb, 2026.

Who are the top competitors of BrainStorm Cell?

BrainStorm Cell's top competitors include Alector, Juvenescence and Annexon. Among them, BrainStorm Cell secured the most recent funding round in February, 2026.

BrainStorm Cell - 2026 Company Profile, Funding, Competitors & Financials

Company Details

BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as ALS (Lou Gehrig's disease), Multiple Sclerosis (MS), and Parkinson’s disease (PD). NurOwn is BrainStorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (MSC) into neurotrophic factor (NTF)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. Its platform technology essentially converts MSCs into living drug delivery systems for NTFS. They use animal models of neurodegenerative diseases, including Parkinson's, Huntington's, ALS, MS, and peripheral nerve injury.

Website: brainstorm-cell.com
Social

Key Metrics

Founded Year

2000

Location

Petah Tikva, Israel

Stage

Public

Latest Funding Round

Post IPO, Feb 09, 2026, $*****

Investors

Iconic Private Equity Partners & 7 more

Ranked

59^th among 492 active competitors

Employee Count

30 as on Mar 31, 2026

Similar Companies

Alector & 623 more

Exit Details

Public

View BrainStorm Cell's full profile

BrainStorm Cell is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BRAINSTORM CELL THERAPEUTICS INC. CIN: 1137883 , United States, Active	Nov 14, 2006	-	-	-

BrainStorm Cell got listed on Sep 08, 2003.

Click here to take a look at BrainStorm Cell's IPO in detail

BrainStorm Cell has raised funding over 10 rounds. Its first funding round was on Jul 27, 2012. BrainStorm Cell has 8 institutional investors.

Here is the list of recent funding rounds of BrainStorm Cell:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 09, 2026	5582757	Post IPO	3880789	3713095	8297309	9873243
Jun 09, 2020	4592499	Grant (prize money)	5387751	4805923	4306019	I AM ALS & 1 more
Apr 03, 2020	2333374	Grant (prize money)	8363929	6797036	4053732	Israel Innovation Authority

Access funding benchmarks and valuations. Sign up today!

View details of BrainStorm Cell's funding rounds and investors

BrainStorm Cell's employee count trend

BrainStorm Cell has 30 employees as of Mar 26. Here is BrainStorm Cell's employee count trend over the years:

Employee count trend for BrainStorm Cell

Uncover BrainStorm Cell's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BrainStorm Cell include Alector, Juvenescence and Annexon. Here is the list of Top 10 competitors of BrainStorm Cell, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	72/100
2nd	Juvenescence 2017, Dublin (Ireland), Series B	Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health	$290M	Ipgl, Foresite Capital & 9 others	68/100
3rd	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, New Enterprise Associates ... & 16 others	67/100
4th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Orbimed, Perceptive Advisors & 5 others	65/100
5th	AviadoBio 2019, London (United Kingdom), Series A	Developer of gene therapies for neurodegenerative disorders	$80M	New Enterprise Associates, Monograph & 9 others	65/100
6th	Axsome Therapeutics 2012, New York City (United States), Public	Developer of therapeutic solutions for the management of CNS disorders	$8.7M	SVB Securities, Collage Venture Partners	65/100
7th	RoosterBio 2012, Frederick (United States), Series B	Developer of human mesenchymal stem cells and extracellular vesicles	$38.4M	Planetary Technologies, Dynamk Capital & 4 others	64/100
8th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Small molecule drugs that target deubiquitylating enzymes involved in the DNA damage response	$192M	Pfizer Venture Investments, Sofinnova Partners ... & 46 others	64/100
9th	Amphista Therapeutics 2018, Motherwell (United Kingdom), Series B	Developer of targeted protein degradation technology-based therapeutics	$60.5M	Advent Life Sciences, Gilde Healthcare & 10 others	64/100
10th	PAQ 2020, Cambridge (United States), Series B	Developer of small molecule therapeutics for neurodegenerative disease	$111M	MRLV, Sherpa Healthcare Partners & 8 others	63/100
59th	BrainStorm Cell 2000, Petah Tikva (Israel), Public	Developer ofstem cell therapies for the treatment of neurodegenerative diseases such as ALS, MS, PD	-	Iconic Private Equity Partners, Vermögensclub ... & 6 others	54/100